- Home
- BJDX vs PPBT Comparison
BJDX vs PPBT Comparison
Compare BJDX & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJDX
- PPBT
- Stock Information
- Founded
- BJDX 2015
- PPBT 2010
- Country
- BJDX United States
- PPBT Israel
- Employees
- BJDX N/A
- PPBT N/A
- Industry
- BJDX Medical Specialities
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- BJDX Health Care
- PPBT Health Care
- Exchange
- BJDX Nasdaq
- PPBT Nasdaq
- Market Cap
- BJDX 2.2M
- PPBT 2.1M
- IPO Year
- BJDX 2021
- PPBT N/A
- Fundamental
- Price
- BJDX $1.57
- PPBT $0.57
- Analyst Decision
- BJDX
- PPBT Strong Buy
- Analyst Count
- BJDX 0
- PPBT 1
- Target Price
- BJDX N/A
- PPBT $33.00
- AVG Volume (30 Days)
- BJDX 148.6K
- PPBT 2.8M
- Earning Date
- BJDX 11-06-2025
- PPBT 08-06-2025
- Dividend Yield
- BJDX N/A
- PPBT N/A
- EPS Growth
- BJDX N/A
- PPBT N/A
- EPS
- BJDX N/A
- PPBT N/A
- Revenue
- BJDX N/A
- PPBT N/A
- Revenue This Year
- BJDX N/A
- PPBT N/A
- Revenue Next Year
- BJDX $55.56
- PPBT N/A
- P/E Ratio
- BJDX N/A
- PPBT N/A
- Revenue Growth
- BJDX N/A
- PPBT N/A
- 52 Week Low
- BJDX $1.26
- PPBT $0.53
- 52 Week High
- BJDX $12.45
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- BJDX 59.29
- PPBT 11.95
- Support Level
- BJDX $1.40
- PPBT $0.53
- Resistance Level
- BJDX $1.51
- PPBT $2.36
- Average True Range (ATR)
- BJDX 0.08
- PPBT 0.16
- MACD
- BJDX 0.02
- PPBT -0.13
- Stochastic Oscillator
- BJDX 77.42
- PPBT 2.05
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.